In addition, using the noninvasive fibrosis risk score (FIB-4), it was reported that the optimal control of blood pressure protects against moderate-to-severe hepatic fibrosis risk [37].In another cross-sectional study among hypertensive patients with NAFLD proven by biopsy, the use of renin-angiotensin-aldosterone system (RAAS)inhibitors combined with either an angiotensin converting enzyme inhibitor (ACE-I) or an angiotensin receptor blocker (ARB) was associated with less advanced hepatic fibrosis compared with the control group [38]. This evidence concerns the gene REN and metabolic dysfunction-associated steatotic liver disease.